Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial-Reference-Cited by-同舟云学术

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

Published:2019-07-17 Issue:11 Volume:8 Page:5079-5088
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Charton Emilie¹²^ORCID,Bachet Jean‐Baptiste³,Hammel Pascal⁴,Desramé Jérôme⁵,Chibaudel Benoist⁶,Cohen Romain⁷,Debourdeau Philippe⁸,Dauba Jérome⁹,Lecomte Thierry¹⁰,Seitz Jean‐François¹¹,Tournigand Christophe¹²,Aparicio Thomas¹³,Guerin‐Meyer Véronique¹⁴,Taieb Julien¹⁵,Volet Julien¹⁶,Louvet Christophe¹⁷,Anota Amélie¹²¹⁸^ORCID,Bonnetain Franck¹²¹⁸

Affiliation:

1. Methodology and Quality of Life Unit in Oncology INSERM UMR 1098University Hospital of Besançon Besançon France

2. University Bourgogne Franche‐Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte‐Greffon‐Tumeur/Ingénierie Cellulaire et Génique Besançon France

3. Department of Hepato‐Gastroenterology, Groupe hospitalier Pitié Salpêtrière Sorbonne University, UPMC University Paris France

4. Department of Digestive Oncology Hôpital Beaujon Clichy France

5. Department of Hepato‐Gastroenterology Hôpital Privé Jean Mermoz Lyon France

6. Department of Oncology Institut Franco‐Britannique Levallois‐Perret France

7. Department of Oncology AP‐HP, Hôpital Saint‐Antoine, Sorbonne University Paris France

8. Department of Oncology Institut Saint Catherine Avignon France

9. Department of Oncology Hôpital Layne Mont de Marsan Mont de Marsan France

10. Department of Hepato‐Gastroenterology Hôpital Trousseau Tours France

11. CHU La Timone Marseille France

12. Department of Oncology CHU Henri Mondor Créteil France

13. Department of Hepato‐Gastroenterology CHU Saint Louis Paris France

14. Department of Oncology Institut de cancérologie de L'Ouest Paul Papin Angers France

15. Department of Gastroenterology and Digestive Oncology Hôpital Européen Georges Pompidou Paris France

16. Department of Hepato‐Gastroenterology CHU Robert Debré Reims France

17. Department of Oncology Institut Mutualiste Montsouris Paris France

18. French National Platform of Quality of Life and Cancer Besançon France

Funder

Institut National Du Cancer

Celgene

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2311

Reference28 articles.

1. Cancer of the Pancreas: A Dilemma in Treatment

2. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

3. European cancer mortality predictions for the year 2014

4. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?

5. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The estimand framework had implications in time to patient-reported outcomes deterioration analyses in cancer clinical trials;Journal of Clinical Epidemiology;2023-10

2. Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review;ESMO Open;2022-12

4. %TTD and %TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology;Computer Methods and Programs in Biomedicine;2022-02

5. Optimal assessment of quality of life for patients with prostate cancer;Therapeutic Advances in Medical Oncology;2022-01